THSNA 2026 - Portland, OR

PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

Workshop Schedule

SATELLITE SYMPOSIA

Host a Satellite Symposium

Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2026 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.

Wed - Mar 18

Thu - Mar 19

Fri - Mar 20

Sat - Mar 21

View Program Details

FRIDAY, MARCH 20

7:00 - 8:00 AM

SATELLITE SYMPOSIUM

ADVANCES IN VON WILLEBRAND DISEASE: FROM GENETICS TO PROPHYLAXIS (SPONSORED BY OCTAPHARMA)
B115-116

This symposium will highlight current and emerging strategies to improving the diagnosis and management of von Willebrand disease (VWD) from genetics to long-term prophylaxis The program will begin with address advances in VWD diagnostics, focusing on the clinical utility of VWF genotyping. The investigator-initiated VUS study will be presented, evaluating whether VWF genotyping improves diagnostic accuracy, variant interpretation, treatment decisions, bleeding-related quality of life, and family testing. The symposium will also explore iron deficiency as an important and often under-recognized comorbidity in VWD. The final part of the symposium will focus on prophylactic treatment strategies in VWD, reviewing data from the WIL-31 and WIL-33 studies demonstrating the effectiveness of VWF concentrate prophylaxis across VWD subtypes and age groups. Planned US-based cost-effectiveness analysis and of concepts of personalized prophylaxis, including the design and rationale of the POPPK study, will be also introduced. The session will be chaired by Veronica Flood, with faculty Robert Sidonio and Jill Johnsen.

JOINT HEALTH AND PHYSICAL ACTIVITY IN PATIENTS WITH HEMOPHILIA A: PANEL DISCUSSION AND TRIVIA WITH EXPERTS (SPONSORED BY GENENTECH)
B113-114

Are you ready to compete? Join us in testing your knowledge on the efficacy and safety data for the first subcutaneous prophylaxis treatment for hemophilia A. This gameshow will highlight pivotal clinical trial data and safety as well as information on joint health and physical activity in patients with hemophilia A. There will be a discussion on experts clinical practice experiences and insights.

7:00 - 8:00 PM

EVENT/OTHER

REGISTRATION
Oregon Ballroom Lobby

8:15 - 9:45 AM

LABORATORY

CHALLENGES IN ANALYZING COAGULATION PARAMETERS--NEW SOLUTIONS TO OLD PROBLEMS?
Chair/Organizer: Kristi Smock, Martha Eva Viveros
Oregon Ballroom 204

8:15

GUIDANCE FOR APPLYING, VERIFYING, AND/OR VALIDATING AI IN THE CLINICAL LABORATORY SETTING
JANSEN SEHEULT.

9:07

HOW NEW GENERATION VWF ASSAYS HAVE CHANGED VWF DIAGNOSIS
CHRISTOPHER NG.

8:15 - 9:45 AM

HEMOSTASIS

CLINICAL CONSIDERATIONS: AGING WITH A BLEEDING DISORDER
Chair/Organizer: Dawn Rotellini, Caroline Kruse
Oregon Ballroom 203

8:15

BONE HEALTH, CONSIDERATIONS AS OUR PATIENTS AGE
CRAIG KESSLER.

8:45

CARDIOVASCULAR CONSIDERATIONS & DRUG INTERACTIONS IN THE CARE OF BLEEDING DISORDERS
JONATHAN ROBERTS.

9:15

PSYCHOSOCIAL CONSIDERATIONS IN AGING PATIENTS WITH BLEEDING DISORDERS
KATHALEEN SCHNUR.

8:15 - 9:45 AM

THROMBOSIS / BASIC SCIENCE

DON'T FORGET THE KIDNEYS! RENAL CONSIDERATIONS IN THROMBOSIS PATHOLOGY AND MANAGEMENT
Chair/Organizer: Jori May, Tara Lech
Oregon Ballroom 201

8:15

BASIC SCIENCE PERSPECTIVE ON THROMBOSIS, DOACS, AND THE KIDNEY
BRYCE KERLIN.

8:45

MICROTHROMBI AND COMPLEMENT MEDIATED RENAL DISEASE
CHRISTOPH LICHT.

9:15

CLINICAL PERSPECTIVE ON ANTICOAGULATION WITH DOACS IN KIDNEY DISEASE
MARISA BATTISTELLA.

9:45 - 10:30 AM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Exhibit Hall A

A1. ANTICOAGULATION CLINICS

400

COMPARING WARFARIN DOSE DECISION MAKING BEFORE AND AFTER TRANSITION TO PATIENT SELF-MANAGEMENT
JACK M. LAWRENCE¹, GEOFFREY D. BARNES², KATELYN W. SYLVESTER³, LINH CHAN⁴, SARA R. VAZQUEZ⁵, AUBREY E. JONES^{1, 5}, SPENCER J. GILBERT^{1, 5}, DANIEL M. WITT^{1, 5}. ¹University of Utah College of Pharmacy, Salt Lake City, UT, USA. ²University of Michigan, Ann Arbor, MI, USA. ³Brigham and Women's Hospital, Boston, MA, USA. ⁴Veterans Affairs Loma Linda Healthcare System, Loma Linda, CA, USA. ⁵University of Utah Health Thrombosis Service, Salt Lake City, UT, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

403

ICOAGLAB MEASURES COMPREHENSIVE COAGULATION PROFILES WITHIN MINUTES IN CARDIAC INTENSIVE CARE PATIENTS
DANIEL HOARE¹, JAY SAGGU², RUSUL AL-ANI², KRISTEN WARREN², ANIKET JOSHI¹, CHRISTOPH NABZDYK², SEEMANTINI NADKARNI¹. ¹Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ²Division of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Brigham and Womena, Boston, MA, USA

404

THROMBOTIC COMPLICATIONS IN SICKLE CELL ANEMIA
BHAKTI SINGH¹, NEHA THOMAS¹, ATUL LADDU¹, FAKIHA SIDDIQUI², JAWED FAREED². ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Chicago, IL, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

405

SEX AND AGE-BASED EVALUATION OF A NEWLY FORMULATED INTRANASAL DDAVP COMPARED WITH INTRANASAL DDAVP AND SUBCUTANEOUS DDAVP IN TYPE 1 VON WILLEBRAND DISEASE
SANJAY AHUJA¹, SWETA GUPTA¹, MAGDALENA LEWANDOWSKA¹, JENNIFER MAAHS¹, SONIA NASR², AMY SHAPIRO¹. ¹Innovative Hematology, Indiana Hemophilia a Thrombosis Center, Indianapolis, IN, USA. ²GLOVAL LLC, Broomfield, CO, USA

406

CYTOKINE RELEASE SYNDROME AND THROMBOSIS RISK AFTER CAR-T THERAPY
COURTNEY CRAWFORD¹, PARMIS SAHRAPIMA¹, JOSEPH SHATZEL^{2, 3}, CORINNE LAVASSEUR^{2, 3}. ¹Department of Internal Medicine, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR, USA. ²Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR, USA. ³Knight Cancer Institute, Portland, OR, USA

407

DEEP VEIN THROMBOSIS FOLLOWING CALF HEMATOMA IN A PEDIATRIC PATIENT WITH FACTOR VII DEFICIENCY
GRACE HAUSE, OMS-II¹, FRED LOEFFLER, PT, DPT, LAT, ATC, CLT², STEPHANIE GARRISON, NP³, NIHAL BAKEER, MD^{3, 4, 5}, EMAN ABDELGHANI, MD³. ¹Marian University Wood College of Osteopathic Medicine, Indianapolis, IN, USA. ²Physical Therapy, Indiana Hemophilia and Thrombosis Center, Innovative Hematology Inc, Indianapolis, IN, USA. ³Innovative Hematology Inc. / Indiana Hemophilia and Thrombosis Center (IHI/IHTC), Indianapolis, IN, USA. ⁴Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁵Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, USA

408

MIM8 PROPHYLAXIS IN ADULTS AND ADOLESCENTS WITH HEMOPHILIA A: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM THE PHASE 3 FRONTIER2 STUDY
STEVEN R LENTZ¹, ABY ABRAHAM², CIHAN AY³, ANTHONY KC CHAN⁴, VICTOR JIMACNEZ-YUSTE⁵, JOHANNES OLDENBURG⁶, MARIA ELISA MANCUSO^{7, 8}, JOHNNY MAHLANGU⁹, TADASHI MATSUSHITA¹⁰, LIZE VAN VULPEN¹¹, RENCHI YANG¹², AMALIE RHODE HACGH NIELSEN¹³, ILGIZ RAKHMATULLIN¹³, EMILY WATERS¹⁴, PRATIMA CHOWDARY¹⁵, MARIA LAGE¹⁴. ¹Department of Internal Medicine, University of Iowa, Iowa City, IA, USA. ²Department of Clinical Haematology, Christian Medical College, Vellore, Tamil Nadu, India. ³Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. ⁴McMaster Childrena, Hamilton, ON, Canada. ⁵Hospital Universitario La Paz, Universidad AutA³noma de Madrid, Madrid, Spain. ⁶The Institute of Experimental Hematology and Transfusion Medicine, UniversitActsklinikum Bonn, Bonn, Germany. ⁷Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. ⁸Humanitas University, Pieve Emanuele, Milan, Italy. ⁹Department of Molecular Medicine and Haematology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa. ¹⁰Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan. ¹¹Center for Benign Haematology, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, Netherlands. ¹²Thrombosis and Hemostasis Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. ¹³Novo Nordisk A/S, SAcborg, Denmark. ¹⁴Novo Nordisk Inc, Plainsboro, NJ, USA. ¹⁵Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, Department of Haematology, University College London, London, United Kingdom

409

VISUALIZATION AND CHARACTERIZATION OF VON WILLEBRAND MULTIMER BANDING PATTERNS IN ACQUIRED VON WILLEBRAND SYNDROME:A RETROSPECTIVE STUDY
SERENA D. NAVITSKAS¹, FATIMA SHABA², RAJIV K. PRUTHI^{1, 2}, DONG CHEN¹, MEERA SRIDHARAN^{1, 2}. ¹Department of Laboratory Medicine, Rochester, MN, USA. ²Department of Medicine, Rochester, MN, USA

410

EMICIZUMAB FOR SEVERE VON WILLEBRAND DISEASE (VWD): THE EMIVWD STUDY ENROLLMENT 2026
JONATHAN C. ROBERTS^{1, 2}, MAY CHIEN³, SWETA GUPTA⁴, ANGELA WEYAND⁵, REBECCA KRUSE-JARRES⁶, ERIN COCKRELL⁷, FERNANDO F. CORRALES-MEDINA⁸, VANESSA SALINAS⁹, SHANNON L. CARPENTER¹⁰, ERIN ESPINOZA¹¹, ABDULRAHEEM YACOUB¹², DAYNA LENSKI¹, SARA MALIK¹, SARAH KREITZER¹, MICHAEL D. TARANTINO^{1, 2}. ¹Bleeding a Clotting Disorders Institute, Dills Family Foundation Center for Research at BCDI, Peoria, IL, USA. ²Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA. ³Stanford University, Stanford, CA, USA. ⁴Innovative Hematology, Indiana Hemophilia and Thrombosis Center, Indianapoils, IN, USA. ⁵University of Michigan Medicine, Ann Arbor, MI, USA. ⁶Washington Center for Bleeding Disorders, Seattle, WA, USA. ⁷St. Josepha, Tampa, FL, USA. ⁸Division of Pediatric Hematology-Oncology, University of Miami Miller School of Medicine, Miami, FL, USA. ⁹Center for Inherited Blood Disorders, Orange, CA, USA. ¹⁰Childrena, Kansas City, MO, USA. ¹¹Tri-Health Cancer Institute, Cincinnati, OH, USA. ¹²University of Kansas Cancer Center, Westwood Kansas, KS, USA

411

HEMOPHILIA LIFE STAGES AND CHANGES GLOBAL SURVEY OF PEOPLE WITH HEMOPHILIA, CAREGIVERS, AND HEMATOLOGISTS: DATA FROM UNITED STATES AND CANADIAN RESPONDENTS
MARK W. SKINNER^{1, 2}, KIM ISENBERG³, PAMELA WILTON⁴, ANDREW WILSON⁵, LYNN MALEC⁶, KYRIE SMITH-JONES⁵. ¹Institute for Policy Advancement, Ltd, Washington, DC, USA. ²Assistant Clinical Professor, McMaster University, Hamilton, ON, Canada. ³Sanofi, Minneapolis, MN, USA. ⁴Canadian Hemophilia Society, Montreal, QC, Canada. ⁵Sanofi, Cambridge, MA, USA. ⁶Versiti Blood Research Institute Associate Professor, Division of Hematology and Oncology, Departments of Medicine and Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA

412

EVALUATION OF D-DIMER IN PATIENTS WITH END-STAGE RENAL DISEASE
SANA VERMA¹, KEERTI CHAKRAVARTHY¹, FAKIHA SIDDIQUI², VINOD BANSAL², JAWED FAREED². ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Chicago, IL, USA

A7. PATHOPHYSIOLOGY OF THROMBOSIS

413

VENOUS THROMBOEMBOLISM OUTCOME-ONLY QUALITY MEASURES FAIL TO PROVIDE ACTIONABLE INFORMATION ABOUT PREVENTION PRACTICES
BRANDYN D. LAU^{1, 2, 3, 4}, MICHAEL B. STREIFF^{1, 2}, DAURYNE L. SHAFFER⁵, PEGGY S. KRAUS⁵, ELLIOTT R. HAUT^{1, 2, 3, 4}. ¹Johns Hopkins School of Medicine, Baltimore, MD, USA. ²Armstrong Institute for Patient Safety and Quality, Baltimore, MD, USA. ³Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA. ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ⁵Johns Hopkins Hospital, Baltimore, MD, USA

A8. ANTITHROMBOTIC THERAPY

414

ONCOLOGY PROVIDER PRACTICES AND PERSPECTIVES ON AMBULATORY THROMBOPROPHYLAXIS
CHRISTINA DI CARLO¹, ZAYYA ZENDO¹, BEATRICE FLORIS², MARIA CHAUDHRY², MOE EL-ZEIN², FATIMA HAMAD², CRISTIAN IANNICELLO², ANDREA CERVI^{1, 3}. ¹1Schulich School of Medicine a Dentistry, London, ON, Canada. ²University of Windsor, Windsor, ON, Canada. ³Department of Medical Oncology, Windsor Regional Cancer Center, Windsor, ON, Canada

415

MECHANISTIC POPULATION PK/PD MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES REGN7508CAT AND REGN9933A2 IN HEALTHY VOLUNTEERS: A FOUNDATION FOR DOSE SELECTION AND CLINICAL TRANSLATION
OLEG MILBERG¹, HISHAM ABDALLAH¹, RACHEL KUDGUS LOKKEN², ROBERT DINGMAN¹, KAROLINE A. MEAGHER¹, MICHAEL E. BURCZYNSKI¹, ETHAN MARIN¹, AARON KITHCART¹, DAVID E. GUTSTEIN¹. ¹Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA. ²Allucent, Cary, NC, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

416

APPROPRIATENESS OF HEPARIN-INDUCED THROMBOCYTOPENIA TESTING AND ASSOCIATED PATIENT OUTCOMES ACROSS INTERMOUNTAIN HEALTH
AMINAH R. ALTALHI, CLINTON S. ANDERSON, SCOTT C. WOLLER, DAVE S. COLLINGRIDGE, GABRIEL V. FONTAINE. Intermountain Health, Salt Lake, UT, USA

417

ADDRESSING TRAVEL BARRIERS IN HEMOPHILIA CARE: FROM NEEDS ASSESSMENT TO REGIONAL SATELLITE CLINIC IMPLEMENTATION
SIDNEY GLASS, ELIZABETH HUNT, ERIKA MARTIN. Virginia Commonwealth University, Richmond, VA, USA

10:30 - 11:30 AM

SHORT TALKS

SHORT TALKS - ANTICOAGULATION THERAPY: BEST PRACTICES AND COMPLICATION MANAGEMENT
Chair/Organizer: Gabe Fontaine, Gordon Minaker
Oregon Ballroom 203

10:30

HEMATOLOGIC EVIDENCE OF IRON DEFICIENCY COMMON BELOW FERRITIN 50 NG/ML
LISA BAUMANN KREUZIGER^{1, 2}, RYAN HANSON³, JULIE KOLINSKI², NATHAN LEDEBOER², ALEXANDRA HARRINGTON², ROBERT NERENZ². ¹Versiti Blood Research Institute, Milwaukee, WI, USA. ²Medical College of Wisconsin, Milwaukee, WI, USA. ³Froedtert Hospital, Milwaukee, WI, USA

10:42

MANAGING NEONATAL CENTRAL VENOUS CATHETER-RELATED THROMBOSIS: A ROLE FOR RIVAROXABAN
MOLLY C EASTERLIN¹, MOHIT MEHRA¹, XINWEN LI¹, WENDY LEUNG¹, ASHWINI LAKSHMANAN², SHAHAB NOORI¹, PHILIPPE FRIEDLICH¹, JOSEPH MILLER¹, JULIE JAFFRAY³. ¹University of Southern California/Children's Hospital Los Angeles, Los Angeles, CA, USA. ²Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. ³University of California, San Diego/Rady Childrena, San Diego, CA, USA

10:54

VALIDATION OF ANTICOAGULANT NEUTRALIZING AGENTS FOR LUPUS ANTICOAGULANT TESTING: COMBINED EVALUATION OF DOAC-STOP AND HEPZYME(THSNAELIZABETH VAN COTT TRAVEL AWARDEE)
GORDON MINAKER¹, STEVEN WONG^{2, 3}, HAMISH NICOLSON^{2, 3}. ¹Department of Internal Medicine, University of British Columbia, Vancouver, BC, Canada. ²Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. ³Providence Health Care, St. Paula, Vancouver, BC, Canada

11:06

INCIDENTAL PULMONARY EMBOLISM: WHEN TREATMENT MAY BE WORSE THAN THE DIAGNOSIS
SOPHIE SAMUEL, ADA SELINA JUTBA, HALEY PARKER, GREGORY PON, JENNIFER CORTES. Memorial Hermann Health System, Houston, TX, USA

11:18

PREDICTION OF ANTICOAGULANT-RELATED BLEEDING IN PATIENTS WITH CANCER ON PRIMARY THROMBOPROPHYLAXIS
KRISTEN M SANFILIPPO^{1, 2}, YAN YAN¹, BRIAN F GAGE¹. ¹Washington University in St. Louis School of Medicine, Saint Louis, MO, USA. ²St. Louis Veterans Administration Medical Center, Saint Louis, MO, USA

SHORT TALKS - DIAGNOSIS, MONITORING, AND PATIENT EXPERIENCE IN BLEEDING DISORDERS
Chair/Organizer: Bethany Samuelson Bannow, Amber Pruett
Oregon Ballroom 204

10:30

GLOBAL REACH AND CLINICAL IMPACT OF VWDTEST. COM: ADVANCING AWARENESS AND EARLY DETECTION OF VON WILLEBRAND DISEASE
FERNANDO F CORRALES-MEDINA^{1, 2}, ROBERT F SIDONIO JR³, VERONICA FLOOD^{4, 5}, ANA BOBAN^{6, 7}, SUSAN HALIMEH⁸, MARASA TERESA A⁹, NATHAN T. CONNELL¹⁰, LAURA VILLARREAL-MARTASNEZ¹¹, ALOK SRIVASTAVA¹², ERIK BERNTORP¹³. ¹Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA. ²University of Miami-Hemophilia and Thrombosis Treatment Center, Miami, FL, USA. ³Associate Professor of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA. ⁴Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA. ⁵Versiti Blood Research Institute, Milwaukee, WI, USA. ⁶Haemophilia Center, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia. ⁷Zagreb University School of Medicine, Zagreb, Croatia. ⁸Gerinnungszentrum Rhein-Ruhr (GZRR), Duisburg, Germany. ⁹La Paz University Hospital, Madrid, Spain. ¹⁰ Boston Bleeding Disorders Center, Brigham and Womena, Boston, MA, USA. ¹¹Dr. Jose Eleuterio Gonzalez Monterrey University Hospital, Monterrey, Mexico. ¹²St. Johna, Bengaluru, India. ¹³Clinical Coagulation Research, Department of Translational Medicine, Lund University, MalmAp, Sweden

10:42

ASSESSING AND DISCUSSING PAIN IN THE HEMOPHILIA CLINIC: ACCEPTABILITY AND FEASIBILITY OF THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) MEASURES OF PAIN INTENSITY, INTERFERENCE AND BEHAVIOR IN ADULT MALES WITH HEMOPHILIA
TYLER W. BUCKNER. University of Colorado School of Medicine, Aurora, CO, USA

10:54

CLINICAL DIAGNOSIS AND MANAGEMENT STRATEGIES IN PERSONS WITH BLEEDING DISORDERS OF UNKNOWN CAUSE: A SCOPING REVIEW
EVANGELINA CLARK¹, LING-YI GUO¹, DIANE LORENZETTI^{2, 3}, RAFAL ASMARO⁴, DAWN GOODYEAR^{4, 5}, NATALIA RYDZ^{4, 5}, JULIA HEWS-GIRARD⁶, ROY KHALIFE^{7, 8}, KELSEY UMINSKI^{4, 5}. ¹Department of Medicine, University of Calgary, Calgary, AB, Canada. ²Health Sciences Library, University of Calgary, Calgary, AB, Canada. ³Department of Community Health Sciences, Calgary, AB, Canada. ⁴Division of Hematology and Hematologic Malignancies, Calgary, AB, Canada. ⁵Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Calgary, AB, Canada. ⁶Faculty of Nursing, University of Calgary, Calgary, AB, Canada. ⁷Ottawa Hospital Research Institute, Ottawa, ON, Canada. ⁸Division of Hematology, Department of Medicine, Ottawa, ON, Canada

11:06

COMPREHENSIVE COAGULATION PROFILES AND FIBRINOLYSIS ASSESSMENT AT THE POINT-OF-CARE FOR POSTPARTUM HEMORRHAGE MONITORING
DANIEL HOARE¹, MICHAELA FARBER², SEEMANTINI NADKARNI¹. ¹Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ²Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Womena, Boston, MA, USA

11:18

NOVEL FIBRINOLYSIS ASSAYS SHOW ALTERATIONS IN CLOT LYSIS IN ADOLESCENTS WITH HEAVY MENSTRUAL BLEEDING AND BLEEDING DISORDER OF UNKNOWN CAUSE
RUCHIKA SHARMA¹, LAURA KETELBOETER², CHAD SKAER², MANOJ PAUL², LINDSEY HARTLAND¹, KENDRA MALONE¹, CHAO XING³, SONG XHANG³, MICHAEL WU⁴, CHRISTIAN KASTRUP², AYESHA ZIA¹. ¹Division of Hematology/Oncology/BMT, Department of Pediatrics, University of Texas Southwestern Medical Center, Children's Health Dallas, Dallas, TX, USA. ²Versiti Blood Research Institite, MIlwaukee, WI, USA. ³O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA. ⁴Division of General Internal Medicine, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA

SHORT TALKS - INFLAMMATION, THROMBOSIS, AND ORGAN INJURY IN SICKLE CELL DISEASE
Chair/Organizer: Samantha Carlson, Roona Sinha
Oregon Ballroom 201

10:30

PATHOGENESIS OF FLU-INDUCED PULMONARY THROMBOSIS IN SICKLE CELL DISEASE MICE. (THSNATRAVEL AWARDEE)
TOMASZ KAMINSKI¹, NICHOLAS SWENDROWSKI¹, PRITHU SUNDD^{1, 2}. ¹Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI, USA. ²Department of Medicine (Hematology and Oncology), Medical College of Wisconsin, Milwaukee, WI, USA

10:42

UPTAKE OF CIRCULATING DNA BY PLATELETS PROMOTES LUNG INJURY IN SICKLE CELL DISEASE(THSNATRAVEL AWARDEE)
FNU MANIKANTA¹, TOMASZ W KAMINSKI¹, AYYANAR SIVANANTHAM¹, NICHOLAS SWENDROWSKI¹, JOSHUA FIELD^{1, 2}, SHANE HOWE¹, PRITHU SUNDD^{1, 2}. ¹Versiti Blood Research Institute, Milwaukee, WI, USA. ²Medical College of Wisconsin, Milwaukee, WI, USA

10:54

RISK AND OUTCOMES OF PULMONARY EMBOLISM IN TRAUMA-ASSOCIATED HOSPITALIZATIONS AMONG INDIVIDUALS WITH SICKLE CELL DISEASE (THSNATRAVEL AWARDEE)
AYOBAMI OLAFIMIHAN¹, VICTORIA OJUKWU², LEWIS HSU³. ¹John H Stroger Hospital of Cook County, Chicago, IL, USA. ²UChealth Parkview Medical Center, Pueblo, CO, USA. ³University of Illinois at Chicago, Chicago, IL, USA

11:06

TLR9 PROTMOTES NEUTROPHIL EXTRACELLULAR TRAPS GENERATION IN SICKLE CELL DISEASE(THSNATRAVEL AWARDEE)
AYYANAR SIVANANTHAM¹, SHANE HOWE², NICHOLAS SWENDROWSKI¹, JOSHUA J FIELD^{2, 3}, PRITHU SUNDD^{1, 4}. ¹Thrombosis and Hemostasis Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI, USA. ²Translational Hematology Program, Versiti Blood Research Institute, Milwaukee, WI, USA. ³Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. ⁴Department of Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI, USA

11:18

EFFECT OF PLASMEPSIN ON VENOUS THROMBOSIS IN SICKLE CELL DISEASE
JINTAO WANG, PAUL SILAGHI, DANIEL T. EITZMAN. University of Michigan, Ann Arbor, MI, USA

11:45 - 12:45 PM

SATELLITE SYMPOSIUM

AN OVERVIEW OF VON WILLEBRAND DISEASE AND ITS TREATMENT (SPONSORED BY TAKEDA)
B110-112

Join us for our satellite symposium featuring an overview of von Willebrand Disease and its treatment. Our distinguished speaker will be Dr. Maissaa Janbain, a hematologist at the Louisiana Center for Bleeding and Clotting Disorders with clinical expertise in inherited bleeding disorders, including von Willebrand disease. Dr. Janbain is engaged in patient care and professional education focused on optimizing diagnosis and management strategies across diverse patient populations.

DIVE DEEPER: GET TO KNOW A TREATMENT OPTION FOR YOUR PATIENTS WITH HEMOPHILIA (SPONSORED BY NOVO NORDISK)
B115-116

Replacement therapy with clotting factor concentrates is the most common treatment for people with hemophilia A or hemophilia B. While there have been advances in the treatment options for people with hemophilia, there remains a need for additional prophylactic non-factor therapy options, especially for people with hemophilia B with and without inhibitors. This program will provide information on a prophylactic treatment option for people with hemophilia B and hemophilia A with and without inhibitors and share results from clinical trials.

FINE-TUNING THE COAGULATION CASCADE: HOW WE CHOOSE FROM EXPANDING OPTIONS FOR PATIENTS WITH HEMOPHILIA (SUPPORTED BY SANOFI)
B113-114

This activity is supported by an educational grant from Sanofi. This activity is provided by Integrity CE, LLC. Clinicians managing hemophilia face challenges keeping pace with rapidly evolving therapies, diverse mechanisms, and complex safety profiles. This program delivers expert-led, evidence-based education to help clinicians effectively apply new treatments, individualize therapy, and align decisions with patient goals, inhibitor status, and real-world practice needs. There are no fees for participating and receiving CME credit for this on-demand activity. During the period of April 9, 2026, to April 21, 2026, participants must visit https://integrityce. com/HemVirtual Read the learning objectives Complete the pretest Study the educational activity Complete the posttest and the evaluation form A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form. A statement of credit will be issued by our system and immediately available to download following your completion of the posttest and evaluation.

12:45 - 1:30 PM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Exhibit Hall A

A4. DISORDERS OF PLATELET NUMBER OR FUNCTION

501

PLATELET DYSFUNCTION IN PEDIATRIC PATIENTS ON THE KETOGENIC DIET
KRISTIN N. MAHER¹, SUSANNA FENSTERMACHER², NABIHA H. SAIFEE³, JASON P. LOCKROW⁴. ¹Department of Pediatrics, Division of Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy, University of Washington, Seattle, WA, USA. ²Division of Pediatric Neurology, Seattle Children's Hospital, Seattle, WA, USA. ³Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. ⁴Department of Neurology, University of Washington, Seattle, WA, USA

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

503

LABORATORY VALIDATION OF TECHNOFLUOR FXIII ACTIVITY ON CEVERON S100 INSTRUMENT
RACHEL R LEGER, JULIANA PEREZ BOTERO, M. D. , DONG CHEN, M. D, PH. D. , RAJIV K PRUTHI, M. B. B. S. Mayo Clinic, Rochester, MN, USA

504

HEAT INACTIVATION OF EFANESOCTOCOG ALFA (ALTUVIIIO) IN PATIENT'S PLASMA TO ACCURATELY DETERMINE FACTOR VIII INHIBITOR TITER BY BETHESDA ASSAY.
ANDREA STAUM, ANDREW PODD, TINA AGOSTINI, GEOFFREY WOOL, BAILEY HUTCHISON, SANDRA HABERICHTER, KENNETH FRIEDMAN. Versiti, Milwaukee, WI, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

505

TRANSAMINASE ELEVATIONS IN THE FITUSIRAN CLINICAL DEVELOPMENT PROGRAM WITH THE ANTITHROMBIN-BASED DOSE REGIMEN
SANJAY AHUJA¹, SAVITA RANGARAJAN^{2, 3}, CHUR-WOO YOU⁴, BULENT ZULFIKAR⁵, ABHIMANYU YARRAMANENI⁶, LAUREL A MENAPACE⁶, YUQIAN SHEN⁶, STEVEN W PIPE⁷. ¹Rainbow Hemostasis a Thrombosis Center, University Hospitals Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA. ²Advanced Centre for Oncology, Haematology and Rare Diseases, K. J. Somaiya Super Specialty Hospital, Mumbai, India. ³Faculty of Medicine, University of Southampton, Southampton, United Kingdom. ⁴Department of Pediatrics, Eulji University School of Medicine, Daejeon, South Korea. ⁵Division of Pediatric Hematology-Oncology, Istanbul University Oncology Institute, Istanbul, Turkey. ⁶Sanofi, Cambridge, MA, USA. ⁷Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA

506

UNDERSTANDING INFORMATION ACCESS, TREATMENT DECISION-MAKING AND TREATMENT SATISFACTION AMONG CAREGIVERS OF CHILDREN WITH &LE;17 YEARS OLD WITH HEMOPHILIA A OR B: PRELIMINARY FINDINGS FROM A SURVEY STUDY
POOJITA DASIKA¹, JENNIFER DAVILA². ¹Albert Einstein College of Medicine, Bronx, NY, USA. ²Albert Einstein College of Medicine, Department of Pediatrics, Bronx, NY, USA

507

FROM EFFICACY TO EXPERIENCE: 52-WEEK PATIENT-REPORTED OUTCOMES WITH MIM8 IN ADOLESCENTS AND ADULTS WITH HEMOPHILIA A WITH OR WITHOUT INHIBITORS (FRONTIER2)
CACDRIC HERMANS¹, SANJAY AHUJA², HAZZA ALZAHRANI³, CIHAN AY⁴, PETER KAMPMANN⁵, SAMYA OBAJI⁶, SOPHIE SUSEN⁷, CIPRIAN IONUT TOMULEASA⁸, LIZE VAN VULPEN⁹, AMALIE RHODE HACGH NIELSEN¹⁰, ILGIZ RAKHMATULLIN¹⁰, EMILY WATERS¹¹, CARMEN ESCURIOLA-ETTINGSHAUSEN¹², ARJUN MENON¹¹. ¹Division of Hematology, Cliniques universitaires Saint-Luc, UniversitAc catholique de Louvain (UCLouvain), Brussels, Belgium. ²Department of Pediatric Hematology and Oncology, Rainbow Babies and Childrena, Cleveland, OH, USA. ³Department of Hematology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. ⁴Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. ⁵Department of Hematology, Rigshospitalet, Copenhagen, Denmark. ⁶Department of Haematology, Cardiff and Vale University Health Board, Cardiff, United Kingdom. ⁷Hemostasis and Transfusion Department, University of Lille, Lille University Hospital, Lille, France. ⁸Department of Hematology, a, Cluj-Napoca, Rumania. ⁹Center for Benign Haematology, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands. ¹⁰Novo Nordisk A/S, SAcborg, Denmark. ¹¹Novo Nordisk, Inc, Plainsboro, NJ, USA. ¹²Haemophilia Centre Rhein Main (HZRM), Frankfurt, Germany

508

PRECISION AND REPRODUCIBILITY OF A NEW AUTOMATED CHEMILUMINESCENT IMMUNOASSAY FOR THE DETECTION OF ANTI-PLATELET FACTOR 4/HEPARIN (PF4/H) IGG ANTIBODIES
NIKI LEONARD, KERRIE JASKAL. Werfen, Bedford, MA, USA

509

BLEED TREATMENT OUTCOMES FROM THE XTEND-ED STUDY IN PATIENTS AGED 50 YEARS AND OLDER
JOHANNES OLDENBURG¹, BARBARA KONKLE², TOSHKO LISSITCHKOV³, PRATIMA CHOWDARY⁴, LIANE KHOO⁵, KATSUYUKI FUTATAKE⁶, ELENA SANTAGOSTINO⁷, HELENA PALMBORG⁸, LINDA BYSTRICKAI⁷, JENNIFER DUMONT⁹, MEREDITH FOSTER⁹, SRIYA GUNAWARDENA¹⁰, ANDREW WILSON¹⁰, ANNETTE VON DRYGALSKI¹¹, SCOTT CLELAND¹⁰. ¹University Hospital Bonn, Bonn, Germany. ²Washington Center for Bleeding Disorders, University of Washington, Washington, WA, USA. ³Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia, Bulgaria. ⁴Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom. ⁵Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, Australia. ⁶Ogikubo Hospital, Tokyo, Japan. ⁷Sobi, Basel, Switzerland. ⁸Sobi, Stockholm, Sweden. ⁹Sanofi, Cambridge, MA, USA. ¹⁰Sanofi, Morristown, NJ, USA. ¹¹Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, CA, USA

510

TREATMENT OF ACQUIRED VON WILLEBRAND'S SYNDROME IN THE SETTING OF MONOCLONAL DYSPROTEINEMIAS
FATIMA SHABA, SERENA NAVITSKAS, ERIN AAKRE, AMANDA HERTEL, DONG CHEN, RAJIV PRUTHI, MEERA SRIDHARAN. Mayo Clinic, Rochester, MN, USA

511

LABORATORY VALIDATION OF ADAMTS-13 ANTIBODY ASSAY
MELISSA S. STUART, RAJIV K. PRUTHI, M. B. B. S, DONG CHEN, M. D, PH. D. . Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA

512

OVERVIEW ON MANAGEMENT OF BREAKTHROUGH BLEEDS AND MAJOR SURGERIES FOLLOWING BLEED MANAGEMENT GUIDELINES DURING THE FITUSIRAN CLINICAL PROGRAM IN PEOPLE WITH HEMOPHILIA
JULIAN ZORRILLA¹, KAAN KAVAKLI², LAISZLA&SUP3; NEMES³, TIENAN ZHU⁴, STEPHANIE P'NG⁵, STEVEN W PIPE⁶, MAREK DEMISSIE⁷, ABHIMANYU YARRAMANENI⁸, YUQIAN SHEN⁷, UMER KHAN⁷, GUY YOUNG⁹. ¹Nemours Childrena, Jacksonville, FL, USA. ²Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey. ³National Haemophilia Center and Haemostasis Department, Center Hospital of Northern Pest - Military Hospital, Budapest, Hungary. ⁴Peking Union Medical College Hospital, Beijing, China. ⁵Fiona Stanley Hospital, Murdoch, Australia. ⁶University of Michigan Medical Center, Department of Hemophilia and Coagulation Disorders, Ann Arbor, MI, USA. ⁷Sanofi, Cambridge, MA, USA. ⁸Sanofi, Morristown, NJ, USA. ⁹Hemostasis and Thrombosis Center, Cancer and Blood Disease Institute, Childrena, Los Angeles, CA, USA

A8. ANTITHROMBOTIC THERAPY

514

EVALUATION OF COMPLIANCE WITH RECOMMENDATION TO TAKE RIVAROXABAN WITH FOOD
NGHI HA, ERIN MOULAND, DENISE SUTTER-LONG, ELIZABETH RENNER, ANISA BICI. Michigan Medicine, Ann Arbor, MI, USA

515

MECHANISTIC POPULATION PK/PD MODELLING OF REGN7508CAT SUPPORTS DOSE SELECTION FOR SUSTAINED FXI SUPPRESSION AND APTT RESPONSE IN HEALTHY VOLUNTEERS AND POST-SURGICAL VTE-PREVENTION PARTICIPANTS
OLEG MILBERG¹, HISHAM ABDALLAH¹, RACHEL KUDGUS LOKKEN², ROBERT DINGMAN¹, KAROLINE A. MEAGHER¹, POULABI BANERJEE¹, MICHAEL E. BURCZYNSKI¹, ETHAN MARIN¹, AARON KITHCART¹, DAVID E. GUTSTEIN¹. ¹Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA. ²Allucent, Cary, NC, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

516

TRANSFORMING AF CARE: A LEARNING LAB APPROACH TO ADVANCING ANTICOAGULATION QUALITY IMPROVEMENT
GEOFFREY BARNES¹, TRACY BLITHE², AMANDA KATZ³, ELIZABETH GOLDSTEIN³, JULIE GOUVEIA-PISANO⁴, CHARLES J MEDICO⁴, BARBARA K PRITCHARD⁴, JULIE SIMONSON⁴, ANNE MARIE SMITH². ¹University of Michigan Medical School, Ann Arbor, MI, USA. ²Heart Rhythm Society, Washington, DC, USA. ³Anticoagulation Forum, Newton, MA, USA. ⁴Pfizer Inc, New York, NY, USA

517

CHARACTERIZING LOW MOLECULAR WEIGHT HEPARIN-ASSOCIATED BLEEDING RISK IN THROMBOLYSIS OR THROMBECTOMY FOR VENOUS THROMBOEMBOLISM
NATASHA JOLAKOSKI, LISA KOSELKE, ALLISON BURNETT. University of New Mexico Hopsital, Albuqerque, NM, USA

518

DISPARITIES IN ANTICOAGULATION PRESCRIBING ACROSS DIFFERENT RACE/ETHNICITIES
ANNJAY TABBILOS, JOE MAZUR, SIENNA MILLER, JENNIFER MAZUR, JULIE ANN EHRET, JOLI FERMO, AGNES MUSYOKA, EMILY OVERLY. Medical University of South Carolina, Charleston, SC, USA

1:30 - 2:45 PM

PLENARY SESSION

WHEN GUIDELINES HIT THE GROUND: IMPACT, IMPLICATIONS AND IMPLEMENTATION
Chair/Organizer: Leo Brandao, Roona Sinha
Oregon Ballroom 201

1:30

IMPACT OF EVIDENCE-BASED GUIDELINES
SUSAN GOODMAN.

1:55

IMPLICATIONS OF GUIDELINES FOR THROMBOSIS & HEMOSTASIS - GOOD, BAD, UGLY? MEDICINE, MONEY AND MALPRACTICE
ADAM CUKER.

2:20

IMPLEMENTATION-HOW TO TRANSLATE GUIDELINE-SUPPORTED EVIDENCE INTO PRACTICE
ANNE SALES.

3:00 - 4:30 PM

LABORATORY / BASIC SCIENCE

INNOVATIVE TECHNOLOGIES FOR CLINICAL LABORATORY PRACTICE
Chair/Organizer: Andy Goodwin, Shannon Meeks
Oregon Ballroom 204

3:00

ROLE OF TISSUE FACTOR TESTING AS A BLEEDING MODIFIER
SOL SCHULMAN.

3:30

PLATELET FUNCTION EVALUATION USING MICROFLUIDICS
NATHAN SNIADECKI.

4:00

HEMOSTASIS ON A CHIP & APP-BASED CLINICAL ASSAYS
WILBUR LAM.

3:00 - 4:30 PM

HEMOSTASIS

REDEFINING GUIDANCE ON BLEEDING DISORDERS IN SPORTS
Chair/Organizer: Caroline Kruse, Bethany Samuelson Bannow
Oregon Ballroom 203

3:00

SPORTS PARTICIPATION IN THE ERA OF INNOVATIVE THERAPIES / WHAT ARE THE CLINICAL BENEFITS OF SPORTS PARTICIPATION IN PATIENTS WITH BLEEDING DISORDERS
CLAYTON KUBRICK.

3:30

DEVELOPING A SHARED DECISION PLAN PRIOR TO TRAINING/SPORTS ACTIVITY
MICHAEL TARANTINO.

4:00

CLINICAL RISKS TO PARTICIPATING IN PHYSICAL EXERCISE AND THE RISK OF INJURY ASSOCIATED WITH PARTICULAR SPORTS/ACTIVITIES
PATRICIA LONGMUIR.

3:00 - 4:30 PM

THROMBOSIS

SPECIAL SITE, SPECIAL STRATEGY: ANTICOAGULATION IN COMPLEX VASCULAR BEDS
Chair/Organizer: Gabe Fontaine, Adam Cuker
Oregon Ballroom 201

3:00

THERAPEUTIC ANTICOAGULATION FOR ARTERIAL THROMBOSIS/REVASCULARIZATION (A DUA, MGH)
ANAHTIA DUA.

3:30

FROM THE VEINS OF LITTLE BRAINS: UPDATES AND DILEMMAS IN PEDIATRIC CEREBRAL SINUS VENOUS THROMBOSIS (CSVT)
SAMYAMI CHOWDHURY.

4:00

MOVING TO MULTIDISCIPLINARY PARADIGM OF MANAGING SPLANCHNIC VEIN THROMBOSIS
JONATHAN BERRY.

4:30 - 5:15 PM

POSTERS/EXHIBITS/BREAK

POSTERS/EXHIBITS/BREAK (click to view) (click to close)
Exhibit Hall A

A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

602

ASSOCIATION OF PEAK GAMMA PRIME FIBRINOGEN LEVELS WITH OUTCOMES IN TRAUMA PATIENTS
LYDIA BUZZARD¹, ALI ORAN², MARTIN SCHREIBER³, DAVID FARRELL¹. ¹Donald D. Trunkey Center for Civilian and Combat Casualty Care, Department of Surgery, Oregon Health a Science University, Portland, OR, USA. ²Department of Surgery, Oregon Health a Science University, Portland, OR, USA. ³Uniformed Services University of the Health Sciences, Bethesda, MD, USA

603

RELEVANCE OF ANNEXIN V WITH COAGULATION FACTORS X AND V IN PULMONARY EMBOLISM PATIENTS
ARYAN MATHUR, MIRA NIGUDKAR, MARTIN LUNDY, FAKIHA SIDDIQUI, DEBRA HOPPENSTEADT, AMIR DARKI, JEANINE WALENGA, JAWED FAREED. Loyola University Stritch School of Medicine, Maywood, IL, USA

604

FACTOR IIA INHIBITORS: MECHANISMS, CLINICAL COMPLICATIONS, AND ADVANCES IN REVERSAL STRATEGIES
PARNIKA TANGUTURU¹, FAKIHA SIDDIQUI², JAWED FAREED². ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Chicago, IL, USA

A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS

605

FITUSIRAN: A NOVEL ANTITHROMBIN-TARGETING THERAPY FOR HEMOPHILIA A AND B, WITH OR WITHOUT INHIBITORS
MOHAMMAD ALASHQAR¹, MILAP NAHATA^{1. 2}. ¹Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus, OH, USA. ²College of Medicine, The Ohio State University, Columbus, OH, USA

606

PREVALENCE OF SOCIAL NEEDS AND THEIR ASSOCIATION WITH HEALTHCARE UTILIZATION IN VON WILLEBRAND DISEASE
ANIKA DHINGRA¹, CHENGSHI JIN^{1, 2}, SOPHIE SHEAN³, ZAHARA JONES³, MARY LESH³, KATRINA UNPINGCO³, ALISON MATSUNAGA^{1, 3}, SHREYA AGARWAL^{1, 3}. ¹School of Medicine, University of California San Francisco, San Francisco, CA, USA. ²Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. ³Division of Hematology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA

608

FRONTIER3: SAFETY AND EFFICACY OF MIM8 PROPHYLAXIS IN PEDIATRIC PATIENTS WITH HEMOPHILIA A
JOHNNY MAHLANGU¹, M. ELAINE EYSTER², KARIN FIJN VAN DRAAT³, GILI KENET⁴, NITA RADHAKRISHNAN⁵, IRENA WOZNICA-KARCZMARZ⁶, RUNHUI WU⁷, CHUR WOO YOU⁸, ANDREA PARAMO FLORENCIO⁹, JAY JAY THAUNG ZAW⁹, EMILY WATERS¹⁰, MANUEL CARCAO¹¹, NIKI PATEL¹⁰. ¹Department of Molecular Medicine and Haematology, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa. ²Department of Medicine, Penn State College of Medicine, Hershey, PA, USA. ³Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, Netherlands. ⁴National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel. ⁵Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, India. ⁶Department of Transfusion Medicine, Children`s University Hospital, Lublin, Poland. ⁷Department of Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. ⁸Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea. ⁹Novo Nordisk A/S, SAcborg, Denmark. ¹⁰Novo Nordisk, Inc, Plainsboro, NJ, USA. ¹¹Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

609

FRONTIER5 DIRECT SWITCH STUDY: SAFETY OF INITIATING MIM8 PROPHYLAXIS WITHOUT WASHOUT OF EMICIZUMAB
JOHANNES OLDENBURG¹, GARY BENSON², PRATIMA CHOWDARY³, ROBERT KLAMROTH^{1, 4}, ANNE LIENHART⁵, DAVIDE MATINO⁶, CAMILA MARTINS MAZINI TAVARES⁷, KEIJI NOGAMI⁸, FLORA PEYVANDI^{9, 10}, AMALIE RHODE HACGH NIELSEN⁷, GUY YOUNG¹¹, EMILY WATERS¹², ALLISON P WHEELER¹³, ATISH PATEL¹². ¹Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany. ²Department of Haematology, Belfast Health and Social Care Trust, Belfast, United Kingdom. ³Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom. ⁴Vivantes Klinikum im Friedrichshain, Berlin, Germany. ⁵Unite d'Hemostase Clinique, Centre de Reference de l'Hemophilie, Hopital Louis Pradel, Lyon, France. ⁶Department of Medicine, McMaster University, Hamilton, ON, Canada. ⁷Novo Nordisk A/S, SAcborg, Denmark. ⁸Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. ⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20122, Milan, Italy. ¹⁰Department of Pathophysiology and Transplantation, UniversitAn degli Studi di Milano, Milan, Italy. ¹¹Cancer and Blood Disease Institute, Childrena, Los Angeles, CA, USA. ¹²Novo Nordisk Inc, Plainsboro, NJ, USA. ¹³Washington Center for Bleeding Disorders, Seattle, WA, USA

610

NON-JOINT BLEEDS IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS: CONCIZUMAB EXPLORER7 STUDY
AMY SHAPIRO¹, ANA BOBAN², RENACE BROWN FRANDSEN³, GIANCARLO CASTAMAN⁴, KINGSLEY HAMPTON⁵, KEIJI NOGAMI⁶, JAMEELA SATHAR⁷, SENTHIL VEL³, JERZY WINDYGA⁸, EMILY WATERS⁹, VICTOR JIMENEZ YUSTE¹⁰, ALLISON DUCHMAN⁹. ¹Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. ²Haemophilia Centre, Department of Haematology, University Hospital Centre Zagreb, Zagreb, Croatia and School of Medicine, University of Zagreb, Zagreb, Croatia. ³Novo Nordisk A/S, SAcborg, Denmark. ⁴Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy. ⁵Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom. ⁶Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan. ⁷Department of Haematology, Ampang Hospital, Kuala Lumpur, Malaysia. ⁸Department of Haemostasis Disorders and Internal Medicine, Laboratory of Haemostasis and Metabolic Diseases, Institute of Haematology and Transfusion Medicine, 02-776, Warsaw, Poland. ⁹Novo Nordisk Inc, Plainsboro, NJ, USA. ¹⁰Department of Haematology, La Paz University Hospital Coagulopathies and Disorders of Haemostasis Group IdiPaz, AutA³noma University, Madrid, Spain

611

EVALUATION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN END-STAGE RENAL DISEASE PATIENTS
RIDDHI SURVE¹, CHARVI CHEGIREDDY¹, FAKIHA SIDDIQUI ², JAWED FAREED², VINOD BANSAL². ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Maywood, IL, USA

A7. PATHOPHYSIOLOGY OF THROMBOSIS

612

EVALUATION OF C-REACTIVE PROTEIN IN END-STAGE RENAL DISEASE PATIENTS
NEHA KOGANTI¹, AARAV GUPTA¹, FAKIHA SIDDIQUI ², JAWED FAREED², VINOD BANSAL². ¹Global Thrombosis Forum, Suwanee, GA, USA. ²Loyola University, Maywood, IL, USA

613

ENROLLMENT CHARACTERISTICS AND REAL-WORLD INSIGHTS INTO DISEASE BURDEN AND GIVOSIRAN TREATMENT IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA IN THE ELEVATE REGISTRY
ELIANE SARDH¹, DAVID CASSIMAN², LAURENT GOUYA³, BRUCE WANG⁴, WEIMING DU⁵, DESMOND MURPHY⁵, TERESA L. KAUF⁵, JAMIE L. WEISS⁵, MANISHA BALWANI⁶. ¹Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. ²Department of Gastroenterology-Hepatology and Center for Metabolic Diseases, University Hospital Leuven, Leuven, Belgium. ³Centre FranAsais des Porphyries, Paris, France. ⁴University of California, San Francisco, CA, USA. ⁵Alnylam Pharmaceuticals, Cambridge, MA, USA. ⁶Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

A8. ANTITHROMBOTIC THERAPY

614

RIVAROXABAN AS SECONDARY THROMBOPROPHYLAXIS IN PEDIATRIC PATIENTS WITH DIGESTIVE MALABSORPTION
ANGELA F JOURNELL ¹, CHELSEA E. PETERS¹, JESSICA MEZNARICH^{1, 2}, SASIDHAR GOTETI^{1, 2}. ¹Primary Children's Hospital, Salt Lake City, UT, USA. ²University of Utah, Salt Lake City, UT, USA

615

EVALUATION OF APIXABAN DOSING PRACTICES FOR VTE/PE IN MEDICALLY COMPLEX PATIENTS
THALIA PADILLA KELLEY¹, REBECCA PONTIUS¹, AAMNA KHAN², MARIE PIATSKI¹, ERIC BLEEM¹, NANCY PADILLA-LAZOS¹, JAKE BERKOWITZ¹, ONYEKACHI ANYA³, ROBERT NIXON¹, KEVIN HUANG¹, CORINNE LAVASSEUR¹, JOSEPH SHATZEL¹. ¹Oregon Health a Science University, Portland, OR, USA. ²Hillsboro Medical Center, Portland, OR, USA. ³ Legacy Salmon Creek Medical Center, Portland, OR, USA

A9. INFORMATIONAL ABSTRACT (POSTER ONLY)

616

REDUCED DOSE COMPARED TO STANDARD DOSE APIXABAN FOR VTE SECONDARY PREVENTION IN PATIENTS WITH ACTIVE CANCER
CLAIRE E. BURBRIDGE, TENLEY E. RYAN, AMANDA R. GILLION. Lt. Col. Luke Weathers Jr. Veterans Affairs Medical Center, Memphis, TN, USA

617

SURGERY IN THE EMICIZUMAB ERA: REAL-WORLD EVIDENCE FROM THE MID-ATLANTIC REGION
JAN G. KUHN¹, ERIKA J. MARTIN¹, REGINA BUTLER², SUSAN GALLAGHER², LISA MAIALE-HOWELL², J. NATHAN HAGSTROM³, ELLE LEVY⁴, DYANNE MORRIS⁵, MARGY SENNETT⁶. ¹Virginia Commonwealth University, Richmond, VA, USA. ²Children's Hospital of Philadelphia, Philadelphia, PA, USA. ³Lehigh Valley Health Network, Allentown, PA, USA. ⁴Childrena, Washington, DC, USA. ⁵University of Pennsylvania, Philadelphia, PA, USA. ⁶University of Virginia, Charlottesville, VA, USA

618

BRIDGING IN HIGH THROMBOEMBOLIC AND VENOUS THROMBOEMBOLISM RISK PATIENTS ON DIRECT ORAL ANTICOAGULANTS: IMPLICATIONS FOR ANTICOAGULATION STEWARDSHIP (BRAVO-HTV)
ITEA THOMALLARI¹, THADDAUS R. HELLWIG^{1, 3}, SHANNON D. WEGLEITNER¹, AMANDA C. OWEN¹, MICHAEL P. GULSETH^{1, 2}. ¹Sanford USD Medical Center, Sioux Falls, SD, USA. ²University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA. ³South Dakota State University College of Pharmacy, Sioux Falls, SD, USA

5:15 - 6:45 PM

THROMBOSIS / HEMOSTASIS

BETWEEN A CLOT AND A HARD PLACE- ANTICOAGULATION IN HIGH BLEED RISK POPULATION
Chair/Organizer: Allison Burnett, Gabe Fontaine
Oregon Ballroom 203

5:15

ANTICOAGULATION IN PATIENTS WITH INHERITED BLEEDING DISORDERS
KIMBERLY YOUKHANA.

5:45

BRAVERY OR BRASHNESS: RESTARTING ANTICOAGULATION IN ICH
GABE FONTAINE.

6:15

MANAGING THROMBOTIC RISK IN PATIENTS WITH LIVER DISEASE
STEPHANIE CARLIN.

5:15 - 6:45 PM

LABORATORY

KIDS ARE NOT LITTLE ADULTS: PEDIATRIC CONSIDERATIONS IN THE HEMOSTASIS/THROMBOSIS LABORATORY
Chair/Organizer: Mara Nunez, Madhvi Rajpurkar
Oregon Ballroom 204

5:15

DIAGNOSTIC STRATEGY FOR VWD MULTIDISIPLINARY COLLABORATION IN PEDIATRICS
MARA NUNEZ.

5:45

D-DIMER IN KIDS VERSUS ADULTS - HOW CAN WE IMPROVE TESTING ALGORITHMS AND LABORATORY TEST UTILIZATION?
CATHY HAYWARD.

6:15

VISCOELASTIC TESTING IN PEDIATRICS
MEERA CHITLUR.

5:15 - 6:45 PM

BASIC SCIENCE

PLATELETS AS AGENTS IN TRANSLATIONAL MEDICINE
Chair/Organizer: Anandi Krishnan, Sol Schulman
Oregon Ballroom 201

5:15

NOVEL APPROACHES TO CRYOEM OF PLATELET SURFACE PROTEINS TO CHARACTERIZE PLATELET DISORDERS
XU HAN.

5:45

BIOMECHANICS OF PLATELET CONTRACTILITY TO IMPROVE DIAGNOSIS OF BLEEDING DISORDERS
NINA SHAVER.

6:15

PLATELETS AS LIQUID BIOPSIES: MULTI-OMIC SIGNATURES IN HUMAN DISEASE
ANANDI KRISHNAN.

7:00 - 8:00 PM

SATELLITE SYMPOSIUM

CABLIVI REAL-WORLD EVIDENCE IN 1, 000+ PATIENTS: WHY EARLY INITIATION MATTERS (SPONSORED BY SANOFI)
B115-116

Timely diagnosis and prompt treatment initiation are essential for improving outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP/iTTP). In this session, we will examine the latest real-world evidence of early treatment initiation with CABLIVI, how early therapeutic strategies influence patient outcomes, the latest updated international treatment guidelines, and highlight healthcare resource utilization data. Attendees will gain practical strategies to optimize treatment timing and enhance care for patients with aTTP/iTTP.

NAVIGATING A NEW FRONTIER IN HEMOPHILIA: EVALUATING THE UTILITY OF EVOLVING FVIIIA MIMETIC THERAPIES TO ADDRESS UNMET NEEDS (THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM NOVO NORDISK, INC. )
B113-114

This activity is jointly provided by AKH Inc, Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. Hemophilia management is entering a new era with innovative factor and nonfactor therapies. This activity explores new and emerging next-generation agents designed to overcome traditional challenges, such as inhibitor development, frequent dosing, and treatment burden. By using interactive, case-based scenarios, learners will develop the expertise needed to individualize patient selection and seamlessly integrate approved and emerging next-generation mimetics into routine practice, fostering a patient-centered approach. 1. 0 AMA PRA Category 1 Credit Register Here: https://hemophiliathsna26. eventbrite. com/